3. Heater NK, Warrior S, Lu J. Current and future immunotherapy for breast cancer. J Hematol Oncol. 2024 Dec 25;17(1):131. doi: 10.1186/s13045-024-01649-z. 4. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients wi...
2. AGOSTINETTO E, LOSURDO A, NADER-MARTA G, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer[J]. Expert Opin Investig Drugs, 2022, 31(6): 567-591. 3. Sch...
Wang K, Yang J, Wang B, et al. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. Translational Breast Cancer Research: A Journal Focusing on Translational Research in Breast Cancer, 2024, 5: 9. 关于特瑞普利单抗注射液(拓益®) 特瑞普利单抗注射液(拓益®)...
Although most breast tumors are not immunogenic, evidence indicates that triple-negative breast cancer (TNBC) expressing PD-L1 is a strong candidate for immunotherapy, explained Leisha A. Emens, MD, PhD, in a presentation on recent trials of immunotherapy alone and in combination with anti—PD-1...
In an interview during the 2018OncLive®State of the Science Summit™ on Breast Cancer, Adams discussed the path forward for immunotherapy in TNBC.Adams: Immunotherapy in breast cancer is a very exciting research area, especially for women who have TNBC. It has been shown that TNBC has visi...
Conclusions This first in human clinical trial of combination chemoradiation, cytokine fusion protein, checkpoint inhibitor, and NK cell therapy demonstrated a safe and tolerable immunotherapy protocol. Early efficacy data is encouraging with a 78% disease control rate, 56% ORR and 22% (2/9) CR ...
But there are other ways of harnessing the immune system. So you'll see clinical trials looking at vaccines and adjuncts to add to immunotherapy. You'll even see clinical trials looking at CAR T-cell therapy and other cellular immune therapies. ...
该方案达到了43.3%的客观缓解率(ORR),且对PD-L1阴性和多线治疗患者也有效,副作用相对较轻,该研究已在《癌症免疫治疗》(Journal for ImmunoTherapy of Cancer)上发表。并且研究中发现PD-L1表达水平并非有效的疗效预测指标,而肿瘤浸润淋巴细胞数量、治疗后CD8+T细胞的增加以及血液中某些细胞因子的变化可能是更好的预测...
Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–72.https://doi.org/10.1038/nri.2017.49. https://doi.org/10.1016/j.immuni.2021.01.012. ...
New results show that adding a novel immune activator, Imprime PGG (Biothera), to immunotherapy withpembrolizumab(Keytruda,Merck) appears to improve the clinical benefit. The overall survival seen with the combination was twice that seen in a separate trial with pembrolizumab alone. ...